美国西雅图的CTI Biophama在上世纪九十年代，根据中国医学的这个信息，把砒霜发展成治疗某一类型白血病的药物。

CTI’s marketing of another drug, Trisenox, was the focus of one Seattle Times story in a 2014 series examining how pharmaceutical companies boost the revenue of limited-scope orphan drugs by encouraging doctors to use them for so-called ‘off-label’ or unapproved conditions. Trisenox was an arsenic compound approved by the Food and Drug Administration for treating a subset of an already rare form of leukemia